AR093182A1 - Metodo para tratar el sobrepeso o la obesidad - Google Patents
Metodo para tratar el sobrepeso o la obesidadInfo
- Publication number
- AR093182A1 AR093182A1 ARP110104512A ARP110104512A AR093182A1 AR 093182 A1 AR093182 A1 AR 093182A1 AR P110104512 A ARP110104512 A AR P110104512A AR P110104512 A ARP110104512 A AR P110104512A AR 093182 A1 AR093182 A1 AR 093182A1
- Authority
- AR
- Argentina
- Prior art keywords
- obesity
- pharmaceutically acceptable
- acceptable salt
- overweight
- bupropion
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 4
- 235000020824 obesity Nutrition 0.000 title abstract 4
- 206010033307 Overweight Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 2
- 229960001058 bupropion Drugs 0.000 abstract 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 2
- 229960003086 naltrexone Drugs 0.000 abstract 2
- 235000012054 meals Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acoustics & Sound (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41939510P | 2010-12-03 | 2010-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093182A1 true AR093182A1 (es) | 2015-05-27 |
Family
ID=46172304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104512A AR093182A1 (es) | 2010-12-03 | 2011-12-02 | Metodo para tratar el sobrepeso o la obesidad |
| ARP210103655A AR124500A2 (es) | 2010-12-03 | 2021-12-23 | Aumento de la biodisponibilidad de droga en terapia naltrexona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103655A AR124500A2 (es) | 2010-12-03 | 2021-12-23 | Aumento de la biodisponibilidad de droga en terapia naltrexona |
Country Status (27)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| EP2292220A3 (en) | 2005-11-22 | 2012-01-04 | Orexigen Therapeutics, Inc. | Composition and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
| PT2646031T (pt) * | 2010-12-03 | 2017-05-25 | Orexigen Therapeutics Inc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
| KR20220042241A (ko) | 2012-06-06 | 2022-04-04 | 오렉시젠 세러퓨틱스 인크. | 과체중 및 비만의 치료 방법 |
| EP3253379A4 (en) * | 2015-02-07 | 2018-10-10 | Intas Pharmaceuticals Limited | Pharmaceutical composition for the treatment of obesity |
| ES2897790T3 (es) * | 2017-03-28 | 2022-03-02 | Ldn Pharma Ltd | Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer |
| EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| EP1772147A2 (en) * | 2003-03-17 | 2007-04-11 | Japan Tobacco, Inc. | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| MXPA05011557A (es) * | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| JP2009502931A (ja) | 2005-07-27 | 2009-01-29 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少を促すための組成物 |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| EP2292220A3 (en) | 2005-11-22 | 2012-01-04 | Orexigen Therapeutics, Inc. | Composition and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| WO2007064586A1 (en) | 2005-11-28 | 2007-06-07 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| DK2526932T3 (en) | 2006-06-19 | 2017-07-17 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| KR101264789B1 (ko) | 2006-06-30 | 2013-05-15 | 엘지디스플레이 주식회사 | 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법 |
| US7915307B2 (en) * | 2006-07-20 | 2011-03-29 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| CN101588795A (zh) * | 2006-11-09 | 2009-11-25 | 奥雷西根治疗公司 | 包含中间快速溶解层的分层药物制剂 |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| LT2545939T (lt) * | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| PT2646031T (pt) * | 2010-12-03 | 2017-05-25 | Orexigen Therapeutics Inc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
-
2011
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 EP EP23209711.3A patent/EP4349369B1/en active Active
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active Active
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 MX MX2017013169A patent/MX384662B/es unknown
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en not_active Ceased
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 SM SM20170232T patent/SMT201700232T1/it unknown
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 FI FIEP23209711.3T patent/FI4349369T3/fi active
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active Active
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Ceased
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 SM SM20240038T patent/SMT202400038T1/it unknown
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active Active
- 2011-12-02 SM SM20210227T patent/SMT202100227T1/it unknown
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Active
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
-
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
-
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
-
2017
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
-
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
-
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
-
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
-
2021
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
-
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
-
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| IN2015DN00376A (cg-RX-API-DMAC7.html) | ||
| CO6630086A2 (es) | Tratamiento de artritis por lupus usando laquinimod | |
| CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| HK1214765A1 (zh) | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 | |
| NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
| RU2018145985A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| IN2015DN00450A (cg-RX-API-DMAC7.html) | ||
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |